FUM Futura Medical Plc

RNS Reach

14 February 2024

Futura Medical plc

("Futura" or the "Company")

Eroxon to be available on prescription
 as well as over the counter

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that its lead product, Eroxon, will be available on prescription in England and Wales for the treatment of Erectile Dysfunction ("ED") with effect from 1^st March 2024. Eroxon is also available without a doctor's prescription having launched in the UK in March 2023.

James Barder, CEO of Futura, commented:

"This milestone builds on the strong progress the Company has made since the initial launch of Eroxon in the UK and is a further step in improving availability of Eroxon, providing access by prescription for men with ED as well as over the counter."

Contacts:

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.